About: NanOlogy
Profile:
Posts by NanOlogy:
- Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood (April 3, 2020 - Home Page, Publications)
- Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage (January 9, 2020 - NanOlogy in the News)
- Video Highlights: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (3-minute version) (November 10, 2019 - Presentations)
- NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas (November 7, 2019 - Home Page, NanOlogy Press Release)
- Video: NanoPac Injection for Pancreatic Cancer | Neil R. Sharma, MD, Parkview Cancer Institute (7-minute version) (November 7, 2019 - Home Page, Presentations)
- ACG 2019 Plenary Presentation: A Novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer. (October 31, 2019 - Presentations)
- ACG 2019 Poster: NanoPac-2017-01 Mid-Study Report: Safety, Tolerability and Preliminary Efficacy of Intracyctic Submicron Particle Paclitaxel (SPP) for the Treatment of Pancreatic Mucinous Cysts (October 31, 2019 - Home Page, Presentations)
- NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac® (October 15, 2019 - NanOlogy Press Release)
- Journal of Aerosol Medicine and Pulmonary Drug Delivery: Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer (August 1, 2019 - Home Page, Publications)
- ATS 2019 Poster: Enhanced Tumor Regression and Immune Cell Infiltration by Inhaled Submicron Particle Paclitaxel (May 21, 2019 - Presentations)
- NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response (May 14, 2019 - NanOlogy Press Release)
- Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial (May 7, 2019 - NanOlogy in the News)
- Cancers 2019: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts (May 3, 2019 - Publications)
- NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer (April 12, 2019 - Home Page, NanOlogy Press Release)
- BIOCEO19 Video: Reshaping Tumor Microenvironments via Immunotherapies. Panel including Gere diZerega, MD, Chief Medical Officer of NanOlogy (February 24, 2019 - Home Page, Presentations)
- ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts (February 19, 2019 - Home Page, Presentations)
- NanOlogy to Present Positive Preclinical Data for NanoDoce® in Treatment of Uro-Oncologic Cancers at 2019 Genitourinary Cancers (ASCO-GU) Symposium (February 13, 2019 - NanOlogy Press Release)
- NanOlogy Chief Medical Officer on Panel to Discuss Next Wave of Innovation in IO Therapy at BIO CEO & Investor Conference (February 5, 2019 - NanOlogy Press Release)
